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ttp://dx.doi.org/10.1016/j.ajpath.2013.10.002We recently discovered elevated b-secretase 1 (BACE1) activity in brains with sporadic Alzheimer dis-
ease (AD). Moreover, we also found high levels of BACE1 enzymatic activity in the cerebrospinal ﬂuid
from patients with both mild cognitive impairment (MCI) and AD. These results suggest that elevation
of BACE1 enzymatic activity may occur early or may contribute to AD. We therefore examined whether
BACE1 enzymatic activity was changed in MCI brains. BACE1 activity and tumor necrosis factor (TNF)-a
levels were measured by enzymatic assay and ELISA in the temporal cortex from 18 patients with
clinically well-characterized AD, 18 patients with MCI, and 18 healthy controls. We found a signiﬁcant
increase in BACE1 activity and protein level in brains of MCI and AD patients. Moreover, increased
BACE1 activity correlated with plaque numbers and cognition status. We also found an increase in TNF-a
in MCI brains. In vitro study revealed that TNF-a rather than other cytokines can up-regulate BACE1
protein expression. These ﬁndings suggest that BACE1 increase occurs early in MCI and is possibly
induced by TNF-a and that BACE1 enzymatic activity may be important for conversion of MCI to AD.
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from the National Institutes of Health, grants IIRG-09-61521 (Y.S.) and
IIRG-07-59510 (R.L.) from the Alzheimer Association, grants G2006-118
(R.L.) and A2008-642 (P.H.) from the American Health Assistance Foun-
dation, grant 81100861 from the National Natural Science Foundation of
China (X.C.), and grant 20100071120081 from the Specialized Research
Fund for the Doctoral Program of Higher Education (X.C.).
Human tissue samples were received from the Brain and Tissue Bank,
Sun Health Research Institute (Sun City, AZ). The Brain and Body
Donation Program is supported by the National Institute of Neurological
Disorders and Stroke (grant U24NS072026 from the National Brain and
Tissue Resource), the National Institute on Aging (grant P30AG19610 from
the Arizona Alzheimer’s Disease Core Center), and the Arizona Department
of Health Services (contract 211002 from the Arizona Alzheimer’s
Research Center).Searching the early events of Alzheimer disease (AD) is
becoming critical for effective diagnosis and treatment.Neuritic
plaques and neuroﬁbrillary tangles are two major pathologic
characteristics of AD and major targets for AD diagnosis.
Amyloid b (Ab) peptide is a major component of neuritic pla-
ques. b-Secretase 1 (BACE1), also known as b-site amyloid
precursor protein (APP) cleaving enzyme, is an aspartic prote-
ase, a critical enzyme to promote Ab generation.1e4 We origi-
nally discovered thatBACE1activity andprotein expression are
signiﬁcantly increased in AD brains.5,6 Because the signals
from cerebrospinal ﬂuid (CSF) reﬂect most of neuropathologic
changes in AD, we have studied BACE1 activity in the CSF
from patients with mild cognitive impairment (MCI) and AD
and found elevatedBACE1 activity in theCSF of bothMCI and
AD patients.7,8 These results indicate that activation of BACE1
may play an important role in the early stage of AD when
cognitive deﬁcits areﬁrst observed and in progressive dementia
associated with AD. However, whether BACE1 enzymatic
activity and protein expression were altered in the brain as early
as at theMCI stagewas not known, possibly because of limits ofstigative Pathology.
.sources of autopsied brain tissues. To examinewhether BACE1
was activated in the brain during the early stages of AD (ie,
MCI),we took advantage of thebrain bank9 of rapidly autopsied
MCI andADbrain tissues and biochemicallymeasuredBACE1
activity in brains of nondemented (ND) controls, MCI patients,
andADpatients.We found thatBACE1 enzymatic activitywas
Cheng et alsigniﬁcantly increased in bothMCIandADbrains in the present
study. Moreover, we also found that BACE1 activity was
positively correlated with numbers of plaques and negatively
correlatedwithMini-MentalStateExamination (MMSE) scores
in MCI patients. Interestingly however, we also observed that
there was no signiﬁcant difference in BACE1 activity between
MCI andADpatients. Because recent studies demonstrated that
BACE1 may affect neuronal activity and brain metabo-
lism,10e13 we conclude that BACE1 activity precedes the
clinical diagnosis of AD and could be an early indicator of
neuronal dysfunction or disease in AD.
Materials and Methods
Brain Samples for Research
Human tissue used in this study was collected with informed
consent of participants or next of kin and with ethical
approval from the institutional review boards of Sun Health
Research Institute (Sun City, AZ). Details of the pathologic
evaluation, including brain autopsy, and Braak staging, as
well as the clinical evaluation, have been previously re-
ported.9 All procedures that involved experiments on
humans were performed in accordance with the ethical
standards of the Committee on Human Experimentation of
Sun Health Research Institute. Temporal cortex samples
from AD, MCI, and ND patients with clinically diagnosed,
neuropathologically conﬁrmed conditions were frozen at
autopsy and stored in vacuum-sealed plastic bags at 80C
until assayed. AD was diagnosed by National Institute of
Neurological and Communicative Disorders and Stroke-
eAlzheimer’s Disease and Related Disorders Association14
criteria and conﬁrmed by autopsy using National Institute
on AgingeReagan Institute Working Group on Diagnostic
Criteria for the Neurological Assessment of Alzheimer’s
Disease.15 MCI was diagnosed according to the Petersen
criteria16 (ie, MCI patients performed 1.5 SDs below the
age-adjusted reference mean in memory scales, as assessed
using the Consortium to Establish a Registry for Alz-
heimer’s Disease cognitive battery,17 including verbal
learning, recognition, and recall tests). Global cognitive
function and activities of daily living were unimpaired in the
MCI subjects. A board-certiﬁed neuropathologist using
Consortium to Establish a Registry for Alzheimer’s Disease
criteria18 performed the neuropathologic evaluation. Post-
mortem intervals averaged<3 hours. We randomly selectedTable 1 Demographic Characteristics of the Study Participants
Group
Total study
participants (No.)
Men/women
(No.) Age (years) PMI
Controls 18 11/7 82.3  6.9 2.6
MCI patients 18 11/7 87.1  4.9 2.7
AD patients 18 8/10 84.6  6.7 2.6
Data are expressed as means  SD unless otherwise indicated.
*Control group, available in nine individuals; MCI group, available in 11 patie
PMI, postmortem interval.
14254 cases, consisting of 18 AD cases, 18 MCI cases, and 18
ND control cases. All of the patients had died from lung or
kidney failure, and they did not have any other central
nervous system (CNS) diseases, sudden death, immuno-
logic disorders, or severe infectious diseases (based on
clinical records and pathologic examination). These 3
groups were well matched with regard to sex, age, post-
mortem interval, and sample preparations (Table 1).
BACE1 Enzymatic Activity Assay
Activity assays of BACE1 were performed as described
previously.19 In brief, samples of human temporal cortex
were lyzed with a lysis buffer (10 mmol/L Tris-HCl, pH 7.4,
150 mmol/L NaCl, 1 mmol/L EDTA, 1 mmol/L EGTA, 1
mmol/L Na3VO4, 10% glycerol, and 0.5% Triton X-100).
BACE1 enzymatic activity assays were performed by using
synthetic peptide substrates containing Swedish mutant
BACE1 cleavage site (Calbiochem, San Diego, CA). BACE1
substrate was dissolved in dimethyl sulfoxide and mixed with
a 100 mmol/L Tris-HCl and 100 mmol/L NaCl, pH 4.5 (pH
adjusted with acetic acid), reaction buffer. An equal amount
of protein was mixed with 100 mL of substrate, and ﬂuores-
cence intensity was measured with a microplate reader
(BioTek, Winooski, VT) at an excitation wavelength of 430
nm and an emission wavelength of 520 nm. For the inhibitor
test experiment, human brain lysate or BACE1 stable cell
lysate was preincubated with 10 nmol/L BACE1-speciﬁc
inhibitor (BACE1 inhibitor IV; Millipore, Billerica, MA) or
1 mmol/L cathepsin D inhibitor pepstatin-A (Millipore) on ice
for 30 minutes and then mixed with substrate for ﬂuorescence
intensity measurement.
Western Blot
The samples of human temporal cortex were individually
homogenized in 1 radioimmunoprecipitation assay buffer,
including a protease inhibitor cocktail (Boehringer Man-
nheim, Indianapolis, IN). Protein concentration was
measured by protein assay (Bio-Rad Laboratories, Hercules,
CA), and 50 to 100 mg of total protein was subjected to SDS-
PAGE (6% to 12% acrylamide). Separated proteins were
then transferred onto polyvinylidene ﬂuoride membranes.
The blots were probed with the following antibodies: anti-
BACE1 polyclonal antibody (Calbiochem), anti-BACE1
monoclonal antibody (R&D Systems, Minneapolis, MN),(h)
History
(years)
APOE ε4
carrier (%)
Last MMSE
(No.)* Plaques (No.)
 0.8 27.8 28.1  1.3 3.1  3.5
 0.7 2  1.7 44.4 27.2  1.8 6.2  4.5
 0.8 8.7  5.2 66.7 10.1  9.4 12.5  1.0
nts; AD group, available in 10 patients.
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Figure 1 A: Western blot shows BACE1 protein expression in the temporal
cortex from the brains of non-demented (ND) controls, Alzheimer disease (AD)
patients, and mild cognitive impairment (MCI) patients. Quantitative analysis
reveals a signiﬁcant increase in BACE1 protein levels in the brains of AD and
MCI patients compared with ND controls. B: BACE1 ELISA conﬁrms the results
of Western blot. C: BACE1 activity assay reveals elevated BACE1 activity in
brains of AD and MCI patients compared with ND controls. The activity was
normalized to the input protein amount and indicated as an arbitrary unit.
nZ 18 for each group. *P < 0.05 versus ND brains.
BACE1 in MCIand antieb-actin monoclonal antibody (1:5000; Sigma-
Aldrich, St. Louis, MO). Western blot measurements were
repeated three times independently.
ELISA
BACE1 protein levels were measured by enzyme-linked
immunosorbent assay (ELISA) as described previously,5,19
with some modiﬁcations. The capture antibody was anti-
BACE1 monoclonal antibody (R&D Systems), and the
detection antibody was biotinylated anti-BACE1 polyclonal
antibody B280. TMB substrate (Thermo Scientiﬁc Pierce,
Rockford, IL) was used to visualize the reaction product,
which was read at OD 450 with a microplate reader (Sigma-
Aldrich). BACE1 protein (Calbiochem) was used as a stan-
dard. Data are presented as means SD of three experiments.
Tumor necrosis factor (TNF)-a levels in the lyzed ex-
tracts were measured by a commercially available ELISA
kit for human TNF-a (R&D Systems). The manufacturer
instructions were used throughout. Dilution curve homog-
enate samples of the brain were parallel to the standard
dilution curve. The absorbance was measured at 450 nm
with an automatic wavelength correction of 540 nm, and
each experiment was repeated three times.
Neurotypical Cell Line Culture
Human SH-SY5Y cells, which can be terminally differenti-
ated into cells that bear numerous speciﬁc characteristics of
neurons as described previously,20 were cultured using 50%
minimal essential medium plus 50% F12 medium, 10% heat-
inactivated fetal calf serum, and 10 mmol/L retinoic acid. The
culture medium was replaced every 3 days, and cells were
differentiated for 6 days. Differentiated cells were seeded on
6-well plates that were precoated with 100 mg/mL of poly-L-
lysine hydrobromide (Sigma-Aldrich) at a density of 1  105
cells/cm2. Differentiated neurotypical SH-SY5Y cells were
grown with the medium based on Neurobasal A supple-
mented with 2% of B27, 2 mmol/L of L-glutamine, and 1% of
N2 supplement (Invitrogen, Carlsbad, CA) at 37C with 5%
CO2. Half volume of the medium was changed every 3 days.
Differentiated SH-SY5Y cells were treated at 6 days with
different concentration of TNF-a and IL-1b (R&D Systems).
After 24 hours, cells were collected and lyzed for Western
blot. Experiments were repeated three times.
Cell Transfection and Luciferase Assay
HEK293 cells were transfected with pB1P-A vector contain-
ing a BACE1 promoter (1941 to þ292) upstream from a
luciferase reporter gene using lipofectamine (Invitrogen).
After transfection, cells were treated with different concen-
trations of TNF-a, IL-8, IL-12, and granulocyte-macrophage
colony-stimulating factor (GM-CSF) (R&D Systems) or NF-
kB inhibitor 6-amino-4(4-phenoxyphenylethylamino) quina-
zoline (Calbiochem). Cells were collected at different timeThe American Journal of Pathology - ajp.amjpathol.orgpoints after treatment, and luciferase assay (Promega, Madi-
son, WI) was performed and luminescence intensity measured
as previously described.19Statistical Analysis
Data are presented as means  SD. Differences in means
were determined by analysis of variance. P < 0.05 was
considered statistically signiﬁcant.Results
Elevated BACE1 Protein Levels in Brains with MCI
We and others have previously demonstrated that signiﬁ-
cantly increased protein levels of BACE1 are observed in the
AD brain.5,6,21,22 By using the same BACE1 antibodies as we
previously described,5,6 Western blots were used to measure
BACE1 protein expression levels. As previously mentioned,6
the yield of total protein did not correlate with age at the time
of death or with the postmortem interval for ND, MCI, or AD
patients (data not shown). It was not surprising that similar
and signiﬁcant elevation of BACE1 protein levels were
observed in AD temporal cortex samples compared with that
of ND samples (Figure 1, A and B). Interestingly, the
Western blot analysis in the samples also revealed a higher
level of BACE1 protein expression in the temporal cortex of
MCI patients than that in the same brain regions of ND
controls. The statistical signiﬁcance (P < 0.05) was reached
after all cases were examined (n Z 18) in each group
(Figure 1, A and B). However, the difference between AD
and MCI was not signiﬁcant (Figure 1), which is consistent
with our previous ﬁndings.5,6 Similar signiﬁcant differences143
Figure 2 A: BACE1 enzymatic activity signiﬁcantly correlates with
plaque numbers in mild cognitive impairment (MCI) brains by linear
regression analysis (rs Z 0.48, P < 0.05). B: Among the 11 MCI patients
who had their last MMSE before death, BACE1 enzymatic activity negatively
correlates with their cognitive function (MMSE scores) by linear regression
analysis (rs Z 0.67, P < 0.05).
Cheng et alwere found in Western blots detected with additional anti-
bodies as published (data not shown).
Increased BACE1 Enzymatic Activity Levels in MCI
Brains
An increased BACE1 protein level is observed in MCI
brains, suggesting similar BACE1 enzymatic activity in
MCI brains as we observed in AD brains.5,6 As for AD
brains, ﬂuorescent-labeled peptide bearing the APP con-
taining the Swedish mutation (APPsw) sequence was used
as a BACE1 enzymatic substrate to test whether the enzyme
from the AD brain crude extracts could cleave the substrate.
As expected, there was an approximately 37% increased
ﬂuorescent intensity in AD temporal cortex extracts
compared with that in ND controls. Importantly, we found
that the ﬂuorescent intensity in MCI temporal cortex ex-
tracts was signiﬁcantly increased by 27% (P < 0.05)
compared with that of ND controls (Figure 1C). In a parallel
test model for another positive control as previously re-
ported,5,6 we transiently transfected BACE1 cDNA into
HEK293 cells stably expressing APPsw. We observed a
high-ﬂuorescent intensity in BACE1-transfected cells, sug-
gesting that BACE1-overexpressing cells have higher
BACE1 activity. In summary, a mixture of APPsw peptide
and MCI and AD crude extracts generated higher ﬂuores-
cent fragment products (127% and 137%, P < 0.05) than
that of the mixture of APPsw peptide and ND extracts
(Figure 1C). Our results suggest that elevated BACE1
enzymatic activity was observed not only in AD brains but
also in MCI brains.
Association of BACE1 Activity with Amyloid Plaque
Burden in the Temporal Cortex Not Only in AD but Also
in MCI Patients
We previously reported that there is a correlation between
BACE1 enzymatic activity and plaque numbers.6 Because
plaques that contain Ab are one of the established patho-
logic hallmarks in the AD brain, BACE1 is one of the
major enzymes in Ab production, and a high level of
BACE1 was found in not only AD but also MCI brains
(Figure 1), we examined a possibility of whether BACE1
activity was correlated with plaque burden in MCI brains.
By using linear regression analysis, we observed a sig-
niﬁcant correlation between levels of BACE1 enzymatic
activity and plaque numbers in MCI brains (Figure 2A).
The data suggest that there is an active and dynamic
AD-related pathologic process during the MCI status, an
early stage of AD.
Selective Changes in Cortical BACE1 Activity as
Cognitive Deﬁcits Merge
We and others have reported the abnormal increase of
BACE1 enzymatic activity in sporadic AD.5,6,21 Moreover,144we also discovered that CSF BACE1 activity was an indi-
cator of the impaired cognitive function in MCI patients.7
We found increased BACE1 activity in MCI brains
(Figure 1). We therefore performed within-subject correla-
tional analyses to determine whether changes in the MCI
brain BACE1 activity (Figure 1C) correspond to cognitive
decline as assessed by the MMSE (Figure 2B). Among 18
MCI patients, 11 had last MMSE before death. Closer in-
spection of enzymatic activity levels across study partici-
pants sorted by cognitive status (Figure 2B) conﬁrmed that
MCI brain cortical BACE1 activity increases during the
earliest stages of dementia. This increase was then followed
by a precipitous decrease as cognitive decline progressed,
which likely accounts for the slightly positive correlation
between MCI brain BACE1 activity and MMSE scores
(Figure 2B).
Increased Proinﬂammatory Cytokine TNF-a Protein
Levels in MCI Brains
Because TNF-a is one of the major inﬂammatory cytokines
in AD brains19,23 and is required for amyloid proteine
induced neuron death,19 it is essential to understand whetherajp.amjpathol.org - The American Journal of Pathology
Figure 3 A: TNF-a concentration elevates in mild cognitive impairment
(MCI) or Alzheimer disease (AD) brains compared with non-demented (ND)
brains. nZ 18 each group. *P < 0.05 versus ND brains. B: With exogenous
TNF-a treatment on human neurons, BACE1 protein expression levels
elevate in a dose-dependent manner, whereas IL-1b appears to have little
effect on BACE1 expression. C: HEK293 cells transfected with a BACE1
promoter luciferase reporter vector were treated with different concentra-
tions of TNF-a with or without NF-kB inhibitor. TNF-a induces BACE1
promoter activity in a dose-dependent manner, whereas NF-kB inhibits
TNF-aeinduced BACE1 promoter activity.
Figure 4 HEK293 cells transfected with a BACE1 promoter luciferase
reporter vector were treated with different concentrations of IL-8 (A), IL-
12 (B), and GM-CSF (C). There are few effects of IL-8, IL-12, and GM-CSF
treatments on BACE1 promoter activity.
BACE1 in MCIprotein levels of TNF-a are changed in the MCI brain.
TNF-a ELISA from identical brain regions of the same
patients revealed a 26% and 36% increase in TNF-a in MCI
and AD temporal tissues, respectively, when compared with
that found in ND controls (Figure 3A). In addition, the TNF-
a increase may not be entirely due to neuronal loss. The
elevation of TNF-a levels may be due to the activation of
glial cells that normally express TNF-a protein in affected
regions of MCI and AD brains. However, no signiﬁcant
difference was observed in TNF-a protein levels between
AD and MCI brains (Figure 3A).The American Journal of Pathology - ajp.amjpathol.orgTNF-a Up-Regulates BACE1 Protein Expression
Because both BACE1 and TNF-a protein levels were
signiﬁcantly increased in the brains of AD and MCI pa-
tients, the next question was whether there was any rela-
tionship between these two molecules. With exogenous
TNF-a treatment on primary human neurons, BACE1 pro-
tein levels were signiﬁcantly increased in a dose-dependent
manner, whereas IL-1b appeared to have little effect on
BACE1 protein expression (Figure 3B).TNF-a Up-Regulates BACE1 Transcription through the
NF-kB Pathway
To clarify how TNF-a up-regulates BACE1 protein
expression, HEK293 cells were transfected with a BACE1
promoter luciferase reporter vector and then treated with
different concentrations of TNFa, IL-8, Il-12, and GM-CSF,
respectively. We found signiﬁcantly increased BACE1
promoter activity in a concentration-dependent manner with
exogenous TNF-a treatment (Figure 3C). However, there
are little effects of IL-8, IL-12, and GM-CSF treatments on
BACE1 promoter activity (Figure 4). Because NF-kB is one
of the major mediators of TNF-aeactivated signaling24 and
multiple NF-kB binding sites are located in the vicinity of
the BACE1 promoter,25 an NF-kB activation inhibitor was
used to block NF-kB signaling in TNF-aetreated HEK293
cells transfected with the BACE1 promoter. Treating the
cells with an NF-kB inhibitor signiﬁcantly reduced145
Cheng et alTNF-aeinduced BACE1 promoter activity (Figure 3C),
suggesting that the up-regulation of BACE1 transcription
may be through TNF-aemediated activation of NF-kB.Discussion
In the present study, we have examined whether BACE1 is
activated in older individuals with ND, MCI, and AD. This
is the ﬁrst report to demonstrate that active BACE1 protein
is intimately associated with MCI patients. The most sig-
niﬁcant ﬁnding is that speciﬁc BACE1 activity exhibits an
obvious elevation in the cortical region, which may be
considered a functional marker of neuropathologic disease
and dementia. Some observed changes were associated with
the mildest stages of cognitive decline, suggesting that
BACE1 activity may be an antecedent to other pathophys-
iologic changes that arise during the disease.
In regard to the speciﬁcity of BACE1 enzymatic assay,
because the BACE1 activity assay chosen may also detect
the activity of cathepsin D, we treated some representative
samples with pepstatin-A, an inhibitor of a number of
aspartyl proteases, such as cathepsin D, that is known to not
affect BACE1 activity. We also have a BACE1 stable cell
line with treatment of BACE1 inhibitor IV C3 and
pepstatin-A. As shown in Supplemental Figure S1, we
found that BACE1 activity signiﬁcantly decreased with
BACE1 inhibitor C3 treatment as expected but not with
pepstatin-A exposure (Supplemental Figure S1), suggesting
pepstatin-A indeed does not affect BACE1. Thus, our assay
of BACE1 activity used in the present study is speciﬁc.
Interestingly, we found elevated BACE1 enzymatic ac-
tivity in MCI patients despite the virtual absence or small
presence of Ab plaques. In general, MCI is considered to be
variable because we know that MCI patients are under
conversion; some of MCI patients convert to AD, whereas
some do not. However, the patients with MCI we studied
had died already of different causes. We assume that these
MCI brain tissues were at the same or similar mental status,
which might be one reason why we have less variability
among MCI brains.
Furthermore, in MCI individuals, the levels of BACE1
activity and protein expression in the temporal cortex are
correlated with the level of cognition. Moreover, the
proinﬂammatory cytokine TNF-a is signiﬁcantly associated
with BACE1 activity in both MCI and AD brains. Our
in vitro studies have found that TNF-a may up-regulate
BACE1 promoter activity (Figure 3C). Although there is
no direct evidence to indicate that Ab and inﬂammation can
cause AD, we found that BACE1, which is regulated by
TNF-a, is increased in MCI brains. Therefore, the present
results indicate that the elevated BACE1 activity occurs
before clinical dementia. Such changes may be regulated by
inﬂammation in the brain, such as TNF-a, a nonspeciﬁc but
potent factor in the development of brain disorders,
including AD and depression.26 We have previously found146that TNF-a and its receptors exhibit differential expression
in AD brains.27 TNF-a is produced by activated microglia,
mainly in response to Ab40 and Ab42 peptides, as well as to
oxidative stress.5,6,19,28 Thus, an increased TNF-a level in
MCI brains is a novel pathologic observation and is
considered only one of the early changed molecules during
MCI. The results suggest that certain nonspeciﬁc stimulus
or environmental changes may trigger expression or release
of inﬂammatory factors (ie, TNF-a), which then further
chronically stimulates BACE1 transcription and translation.
Our results are consistent with previous reports that indicate
that oxidative stress is involved in the prodromal stage of
AD.29,30 As we discussed above, oxidative stress and cy-
tokines are active, dynamic, and critical early events of
MCI. However, a series of rigorous studies would be needed
before we can draw any conclusions that these are the
causes of AD. Our results provide possible explanations for
previous pathologic observations: elevation of CSF BACE1
activity in MCI patients or the presence of an active and
dynamic AD-related pathologic process during the MCI
status, an early stage of AD.
The increased association of BACE1 activity with Ab
plaque burdens from MCI and AD cortex tissues suggests
that BACE1 activity is elevated as a function of disease
state. Increasing evidence suggests that BACE1 is intri-
cately involved in the pathogenesis of AD.31 The present
study investigated BACE1 activity in MCI brains using our
established assays, which allows more powerful statistical
analyses. We conﬁrmed and extended our earlier discoveries
that BACE1 expression is elevated in AD5,6 compared with
age-matched control cases.
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